Stifel, a leading investment bank, has initiated coverage on US-based biotech firm Candel Therapeutics with a buy rating and a price target of £22 per share. The move comes as the broader market shows cautious optimism, with the FTSE 100 closing at 8,214.5 points on Friday, up 0.3% on the day but largely flat over the week. The FTSE 250, more reflective of mid-cap domestic firms, edged 0.1% higher to 20,987.2 points.
Candel Therapeutics, which focuses on developing viral immunotherapies for cancer, has attracted analyst attention following recent clinical trial updates. Stifel's analysts highlighted the company's pipeline potential, particularly its lead candidate for prostate cancer, as a key driver for the £22 target. The initiation of coverage signals confidence in the biotech's near-term prospects, though the stock remains volatile.
The broader market backdrop remains mixed for UK investors. The FTSE 100's lacklustre performance reflects ongoing concerns over inflation and interest rates, with the Bank of England holding rates at 5.25% last month. Sectors such as energy and financials have dragged, while healthcare and biotech have offered pockets of growth. For pension holders with exposure to global equities, the Stifel note adds a positive note on a niche but high-risk area.
Analysts at other firms have yet to weigh in, but Stifel's initiation could prompt further coverage. The £22 target represents a potential upside of over 40% from current levels, though investors are reminded that biotech stocks carry significant clinical and regulatory risks. The FTSE All-Share index, a broader measure of UK-listed equities, slipped 0.1% to 4,503.8 points, with trading volumes subdued ahead of the summer break.
For UK investors, the Stifel note underscores the importance of diversification. While the domestic market remains range-bound, opportunities in innovative sectors like biotech may offer growth, albeit with higher volatility. No investment advice is implied; readers should consult a financial adviser for personalised guidance.